Annual D&A
$464.00 K
-$1.98 M-81.03%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual depreciation & amortization is currently $464.00 thousand, with the most recent change of -$1.98 million (-81.03%) on 31 December 2023. During the last 3 years, it has fallen by -$2.19 million (-82.48%). EYPT annual D&A is now -94.68% below its all-time high of $8.72 million, reached on 30 June 2007.EYPT Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$408.00 K
+$46.00 K+12.71%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly depreciation & amortization is currently $408.00 thousand, with the most recent change of +$46.00 thousand (+12.71%) on 30 September 2024. Over the past year, it has increased by +$293.00 thousand (+254.78%). EYPT quarterly D&A is now -63.28% below its all-time high of $1.11 million, reached on 30 September 2007.EYPT Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$1.19 M
+$293.00 K+32.85%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM depreciation & amortization is currently $1.19 million, with the most recent change of +$293.00 thousand (+32.85%) on 30 September 2024. Over the past year, it has increased by +$498.00 thousand (+72.49%). EYPT TTM D&A is now -72.33% below its all-time high of $4.28 million, reached on 30 June 2008.EYPT TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -81.0% | +254.8% | +72.5% |
| 3 y3 years | -82.5% | -41.8% | -56.8% |
| 5 y5 years | -65.0% | -36.8% | -39.4% |
EYPT Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -83.3% | at low | -42.6% | +288.6% | -57.8% | +155.4% |
| 5 y | 5 years | -83.3% | at low | -42.6% | +288.6% | -57.8% | +155.4% |
| alltime | all time | -94.7% | +118.8% | -63.3% | +848.8% | -72.3% | +155.4% |
EyePoint Pharmaceuticals Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $408.00 K(+12.7%) | $1.19 M(+32.8%) |
| June 2024 | - | $362.00 K(+19.5%) | $892.00 K(+34.7%) |
| Mar 2024 | - | $303.00 K(+170.5%) | $662.00 K(+42.7%) |
| Dec 2023 | $464.00 K(-81.0%) | $112.00 K(-2.6%) | $464.00 K(-32.5%) |
| Sept 2023 | - | $115.00 K(-12.9%) | $687.00 K(-46.5%) |
| June 2023 | - | $132.00 K(+25.7%) | $1.28 M(-30.8%) |
| Mar 2023 | - | $105.00 K(-68.7%) | $1.85 M(-24.2%) |
| Dec 2022 | $2.45 M(-11.7%) | $335.00 K(-52.9%) | $2.45 M(-12.9%) |
| Sept 2022 | - | $711.00 K(+1.0%) | $2.81 M(+0.4%) |
| June 2022 | - | $704.00 K(+1.1%) | $2.80 M(+0.7%) |
| Mar 2022 | - | $696.00 K(-0.3%) | $2.78 M(+0.3%) |
| Dec 2021 | $2.77 M(+4.6%) | $698.00 K(-0.4%) | $2.77 M(+1.1%) |
| Sept 2021 | - | $701.00 K(+2.3%) | $2.74 M(+1.4%) |
| June 2021 | - | $685.00 K(-0.3%) | $2.70 M(+0.6%) |
| Mar 2021 | - | $687.00 K(+2.7%) | $2.69 M(+1.5%) |
| Dec 2020 | $2.65 M(+1.7%) | $669.00 K(+1.1%) | $2.65 M(+0.7%) |
| Sept 2020 | - | $662.00 K(-1.2%) | $2.63 M(+0.6%) |
| June 2020 | - | $670.00 K(+3.4%) | $2.61 M(+0.8%) |
| Mar 2020 | - | $648.00 K(-0.3%) | $2.59 M(-0.4%) |
| Dec 2019 | $2.60 M(+96.4%) | $650.00 K(+0.6%) | $2.60 M(+33.3%) |
| Sept 2019 | - | $646.00 K(-0.5%) | $1.95 M(-0.6%) |
| June 2019 | - | $649.00 K(-1.5%) | $1.97 M(-0.4%) |
| Mar 2019 | - | $659.00 K(+0.2%) | $1.97 M(+24.5%) |
| Dec 2018 | $1.33 M(+15.5%) | - | - |
| Sept 2018 | - | $658.00 K(+0.3%) | $1.58 M(+38.1%) |
| June 2018 | $1.15 M(+40.9%) | $656.00 K(+1425.6%) | $1.15 M(+62.6%) |
| Mar 2018 | - | $43.00 K(-81.1%) | $706.00 K(-18.8%) |
| Dec 2017 | - | $228.00 K(+3.2%) | $869.00 K(+2.6%) |
| Sept 2017 | - | $221.00 K(+3.3%) | $847.00 K(+3.9%) |
| June 2017 | $815.00 K(-10.2%) | $214.00 K(+3.9%) | $815.00 K(-4.3%) |
| Mar 2017 | - | $206.00 K(0.0%) | $852.00 K(-1.2%) |
| Dec 2016 | - | $206.00 K(+9.0%) | $862.00 K(-1.6%) |
| Sept 2016 | - | $189.00 K(-24.7%) | $876.00 K(-3.5%) |
| June 2016 | $908.00 K(+2.9%) | $251.00 K(+16.2%) | $908.00 K(+3.1%) |
| Mar 2016 | - | $216.00 K(-1.8%) | $881.00 K(+0.5%) |
| Dec 2015 | - | $220.00 K(-0.5%) | $877.00 K(+0.6%) |
| Sept 2015 | - | $221.00 K(-1.3%) | $872.00 K(-1.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | $882.00 K(-3.8%) | $224.00 K(+5.7%) | $882.00 K(-0.9%) |
| Mar 2015 | - | $212.00 K(-1.4%) | $890.00 K(-2.1%) |
| Dec 2014 | - | $215.00 K(-6.9%) | $909.00 K(-0.9%) |
| Sept 2014 | - | $231.00 K(-0.4%) | $917.00 K(0.0%) |
| June 2014 | $917.00 K(-7.7%) | $232.00 K(+0.4%) | $917.00 K(-1.7%) |
| Mar 2014 | - | $231.00 K(+3.6%) | $933.00 K(-1.9%) |
| Dec 2013 | - | $223.00 K(-3.5%) | $951.00 K(-2.7%) |
| Sept 2013 | - | $231.00 K(-6.9%) | $977.00 K(-1.7%) |
| June 2013 | $994.00 K(-55.4%) | $248.00 K(-0.4%) | $994.00 K(-2.3%) |
| Mar 2013 | - | $249.00 K(0.0%) | $1.02 M(+1.3%) |
| Dec 2012 | - | $249.00 K(+0.4%) | $1.00 M(-37.9%) |
| Sept 2012 | - | $248.00 K(-8.5%) | $1.62 M(-27.3%) |
| June 2012 | $2.23 M(-33.6%) | $271.00 K(+14.8%) | $2.23 M(-20.8%) |
| Mar 2012 | - | $236.00 K(-72.7%) | $2.81 M(-17.8%) |
| Dec 2011 | - | $863.00 K(+0.7%) | $3.42 M(+0.8%) |
| Sept 2011 | - | $857.00 K(+0.2%) | $3.39 M(+1.1%) |
| June 2011 | $3.35 M(+0.9%) | $855.00 K(+1.3%) | $3.35 M(+1.7%) |
| Mar 2011 | - | $844.00 K(+1.1%) | $3.30 M(+0.6%) |
| Dec 2010 | - | $835.00 K(+1.7%) | $3.28 M(-0.4%) |
| Sept 2010 | - | $821.00 K(+2.6%) | $3.29 M(-1.0%) |
| June 2010 | $3.33 M(-3.3%) | $800.00 K(-2.8%) | $3.33 M(-0.7%) |
| Mar 2010 | - | $823.00 K(-3.1%) | $3.35 M(+0.8%) |
| Dec 2009 | - | $849.00 K(-0.6%) | $3.32 M(-0.0%) |
| Sept 2009 | - | $854.00 K(+3.6%) | $3.32 M(-3.3%) |
| June 2009 | $3.44 M(-19.7%) | $824.00 K(+3.6%) | $3.44 M(-5.8%) |
| Mar 2009 | - | $795.00 K(-6.5%) | $3.65 M(-6.0%) |
| Dec 2008 | - | $850.00 K(-12.3%) | $3.88 M(-6.2%) |
| Sept 2008 | - | $969.00 K(-6.6%) | $4.14 M(-3.3%) |
| June 2008 | $4.28 M(-50.9%) | $1.04 M(+1.0%) | $4.28 M(+31.9%) |
| Mar 2008 | - | $1.03 M(-7.3%) | $3.25 M(+46.3%) |
| Dec 2007 | - | $1.11 M(-0.3%) | $2.22 M(+99.7%) |
| Sept 2007 | - | $1.11 M | $1.11 M |
| June 2007 | $8.72 M(+0.2%) | - | - |
| June 2006 | $8.70 M(+70.2%) | - | - |
| June 2005 | $5.11 M(+2022.0%) | - | - |
| June 2004 | $240.90 K(+13.6%) | - | - |
| June 2003 | $212.10 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual depreciation & amortization?
- What is the all time high annual D&A for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual D&A year-on-year change?
- What is EyePoint Pharmaceuticals quarterly depreciation & amortization?
- What is the all time high quarterly D&A for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly D&A year-on-year change?
- What is EyePoint Pharmaceuticals TTM depreciation & amortization?
- What is the all time high TTM D&A for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM D&A year-on-year change?
What is EyePoint Pharmaceuticals annual depreciation & amortization?
The current annual D&A of EYPT is $464.00 K
What is the all time high annual D&A for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual depreciation & amortization is $8.72 M
What is EyePoint Pharmaceuticals annual D&A year-on-year change?
Over the past year, EYPT annual depreciation & amortization has changed by -$1.98 M (-81.03%)
What is EyePoint Pharmaceuticals quarterly depreciation & amortization?
The current quarterly D&A of EYPT is $408.00 K
What is the all time high quarterly D&A for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly depreciation & amortization is $1.11 M
What is EyePoint Pharmaceuticals quarterly D&A year-on-year change?
Over the past year, EYPT quarterly depreciation & amortization has changed by +$293.00 K (+254.78%)
What is EyePoint Pharmaceuticals TTM depreciation & amortization?
The current TTM D&A of EYPT is $1.19 M
What is the all time high TTM D&A for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM depreciation & amortization is $4.28 M
What is EyePoint Pharmaceuticals TTM D&A year-on-year change?
Over the past year, EYPT TTM depreciation & amortization has changed by +$498.00 K (+72.49%)